Replies to post #2267 on Dendreon Corp fka DNDNQ

[walldiver]

Yep...interesting that Scher gets to be a voting member while the guy with a lot of immunotherapy experience can't vote because of a conflict of interest with CEGE. It's Sanofi who could be threatened by Provenge approval--not Cell Genesys. CEGE doesn't have an approved product yet for PCa. This just goes to show how much differently bureaucrats see things than the rest of us.

[cattoes]

[[Disclosure: Howard I. Scher, MD, has disclosed that he has received grants for clinical research from Sanofi-Aventis.]]

A thumbs down from Scher will call into question his motivation, as it will be coming from a recipient of grant funds directly tied to a company that will lose income, and disease treatment status, if Provenge is approved. It will also take him personally from the epicenter of treatment options surrounding this disease, and instantly render his expertise as partially antiquated. IMO, he should withdraw from participation on the panel, and if he doesn't, then von E should do it for him.